This Year's Highlights

• MT103 Oral Efficacy ? 2nd lung tumor cell line (HOP-92) in vivo study demonstrated oral efficacy comparable to cisplatin (injection). Presented poster with University of Minnesota at AACR, April ?05.
• MT477 - Demonstrated superiority to cisplatin in xenograft studies at the University of Minnesota. Spring, 2006.

Anticipated Highlights

• License initial lead candidate to pharmaceutical or biotechnology partner
• Complete significant financing (Series B) to create infectious disease portfolio and develop/sell current oncology candidates.

Corporate Mission

Medisyn seeks to become the preeminent source of new chemical scaffolds for drug discovery. This is accomplished through use of a proprietary and unique modeling capability based on topological numerical analysis. The technology allows drug-like characteristics to be "built-in" up-front, thereby reducing risk and accelerating drug development. The technology allows analysis and optimization of currently existing drugs to help our partners make go/no go decisions early in the development process, or develop new drug candidates that are pre-screened for effectiveness, safety, potency and mechanism of action. In short, Medisyn can accelerate the process and reduce the risk of drug discovery.